Drug donanemab seen as turning point in dementia fight - eviltoast

The antibody treatment donanemab slows clinical decline by around a third, a large trial confirms.

  • FaceDeer@kbin.social
    link
    fedilink
    arrow-up
    4
    ·
    1 year ago

    The results regarding amyloid plaques just keep going back and forth over time, I’m very curious how this will ultimately play out. I suppose even if the plaques are a symptom rather than the underlying cause it can still be helpful clearing them away.

  • BoCanCan@kbin.social
    link
    fedilink
    arrow-up
    4
    ·
    1 year ago

    It delays dementia by 4-7 months, and also causes bleeding and swelling in the brain which killed 3 out of 1,700 participants in the study.

    It’s better than nothing I guess but it’s not a particularly good treatment.

    • OptimisticPrime@lemmy.fmhy.ml
      link
      fedilink
      arrow-up
      2
      ·
      edit-2
      1 year ago

      Sure, but treatments of something that complex has to start somewhere. It seems to go in the right direction and upcoming treatments may build on that. I am not sure that anyone could have expected after many failures to just find the magical cure that completely cures Alzheimers.